Ulutas, OzkanTaskapan, HulyaTaskapan, Mehmet CagatayTemel, Ismail2024-08-042024-08-0420130301-16231573-2584https://doi.org/10.1007/s11255-012-0308-8https://hdl.handle.net/11616/96115Associations between 25 hydroxy vitamin D [25(OH)D], adipokines levels, and insulin resistance have been reported. The aim of this study was to explore the effects of cholecalciferol supplementation on vitamin D levels, insulin resistance, leptin, and adiponectin levels in vitamin D-deficient peritoneal dialysis (PD) patients. In nineteen vitamin D-deficient PD patients, who were treated with cholecalciferol, fasting serum glucose, insulin, adiponectin, leptin, 25(OH)D and parathyroid hormone (PTH) were measured before and after cholecalciferol replacement therapy. Eighteen (94.7 %) PD patients with vitamin D deficiency were receiving active vitamin D compounds (alphacalciferol) for PTH control. Alphacalciferol dosing was kept constant during treatment with cholecalciferol. While mean 25(OH)D significantly increased from (10.2 +/- A 4.9 ng/ml) to (82.9 +/- A 56.5 ng/ml) (p < 0.05), mean homeostatic model assessment-insulin resistance index significantly decreased from (4.6 +/- A 3.6) to (2.8 +/- A 2.0) after cholecalciferol replacement therapy (p < 0.05). Serum leptin levels (12.9 +/- A 17.6 ng/ml) significantly increased (18.1 +/- A 19.5 ng/ml) (p < 0.05), while there was no change in serum adiponectin, calcium, and phosphate after vitamin D replacement. Serum PTH levels significantly decreased from 551.9 +/- A 276.6 pg/ml to 434.0 +/- A 273.4 ng/ml. Cholecalciferol replacement therapy significantly decreases PTH levels and insulin resistance. The results of this study need to be confirmed in larger clinical trials.eninfo:eu-repo/semantics/closedAccessCholecalciferol replacementInsulin sensitivityVitamin D deficiencyAdiponectinLeptinArticle4538798842306543410.1007/s11255-012-0308-82-s2.0-84879504116Q2WOS:000320843400041Q3